Fig. 1

Tumor IFI35 correlates with CD8⁺ T cells expression and patient outcome. A Screening of CTL function-correlated genes associated with good prognosis in human colorectal cancer. In the TCGA dataset, 412 top genes were identified as positively correlated with Cytolytic Activity (CYT) Score in pan-cancer using Spearman correlation analysis. Among the shared 412 genes, based on our own CRC proteomics, 19 proteins were identified to be correlated with CTL function signature on the protein level using Spearman correlation analysis. The proteomic analysis detected 6 out of 19 proteins with a good prognosis in CRC through Kaplan–Meier analysis. B, C IFI35 expression in normal colorectal tissues and colorectal cancer tissues. B Statistical analysis of IFI35 mRNA levels of 66 paired samples of CRC and adjacent normal tissues from the Sixth Affiliated Hospital (n = 66, non-parametric Wilcoxon matched-pairs signed rank test, p < 0.01). C IFI35 protein expression in colorectal adenocarcinoma tissues (n = 90) and normal colorectal tissues (n = 30). Two tailed t-tests, p < 0. 01. D–G Kaplan–Meier analyses of the association of overall survival with IFI35 proteins. D Overall survival analysis in CRC with low (n = 14) and high (n = 101) levels of IFI35 in 115 CRC patients from our CRC proteomics datasets, E overall survival analysis in CRC with low (n = 81) and high (n = 64) levels of IFI35 in 145 CRC patients from Shanghai’ proteomics datasets, F overall survival analysis in CRC with low (n = 69) and high (n = 487) levels of IFI35 in 556 CRC patients from GSE39582, G overall survival analysis in CRC with low (n = 85) and high (n = 105) levels of IFI35 in 190 CRC patients from GSE87211. Log-rank test. The optimal cutoff values were calculated by the X-tile software. H, I Expression of IFI35 protein and its prognostic value in CRC. H The expression of IFI35 in CRC was detected by Fluorescent Immunohistochemistry analysis based on tissue microarray. I Patients with high expression of IFI35 (n = 80) showed better overall survival time than the patients with low expression of IFI35 (n = 89). J, K Relationship between IFI35 expression and immunotherapy efficacy in melanoma patients. J Overall survival analysis in melanoma with low (n = 21) and high (n = 20) levels of IFI35 treated with Anti-PD1 therapy. K Progression-free survival was analyzed and compared between patients with low (n = 8) and high (n = 7) levels of IFI35 in melanoma patients treated with Anti-CTLA4 therapy. Log-rank test